From owner-sci-resources@net.bio.net Mon Aug 01 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 31 July 1994 Date: 1 Aug 1994 20:01:59 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 78 Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <31kcv7$r9b@net.bio.net> NNTP-Posting-Host: net.bio.net This message contains a summary of the documents added to the NSF STIS system in the previous week. Reference material concerning STIS follows the summary. ------------------------------------------------------------------------ ** NEW DOCUMENTS ON STIS ** Document Type: Program Guideline Title: Faculty Early Career Development (CAREER) Program File size (bytes): 30974 STIS Filename: nsf94101 ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: Phone Book Title: NSF Alpha Telephone Directory File size (bytes): 100822 STIS Filename: phnalpha Title: NSF Organizational Directory File size (bytes): 124413 STIS Filename: phnorg Document Type: Program Guideline Title: NSF 94-96 Macromolecular Structure Database Program Announcement File size (bytes): 27535 STIS Filename: nsf9496 Document Type: Recruit Title: Senior Executive Service Nationwide Vacancy Listing File size (bytes): 57855 STIS Filename: sesvac ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserve@nsf.gov (Internet). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve sesvac, the text of your message should be as follows: get sesvac Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve sesvac, you would enter: ftp> get sesvac WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "pubs@nsf.gov" (Internet). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet). From owner-sci-resources@net.bio.net Wed Aug 03 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 23, no. 29, pt. 1of1, 5 August 1994 Date: 4 Aug 1994 13:35:06 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 1461 Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <31rjdq$uf@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19940805 V23N29 P1O1 ************************************ X-comment: RFAs described: HL-94-018, CA-94-028 NIH GUIDE - Vol. 23, No. 29 - August 5, 1994 $$INDEX BEGIN ******************************************************* NOTICES OF AVAILABILITY (RFPs AND RFAs) $$INDEX R1 ********************************************************** INNOVATIVE VENTRICULAR ASSIST SYSTEM (RFP NHLBI-HV-94-25) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R2 ********************************************************** SYNTHESIS AND TESTING OF NEW ANTIPROGESTATIONAL AGENTS (RFP NICHD-CD- 94-13) National Institute of Child Health and Human Development INDEX: CHILD HEALTH, HUMAN DEVELOPMENT $$INDEX R3 10/20/94 ************************************************* NHLBI MINORITY TRAINING AND DEVELOPMENT PROGRAMS (RFA HL-94-018) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R4 11/23/94 ************************************************* MOLECULAR EPIDEMIOLOGY OF PROSTATE CARCINOGENESIS (RFA CA-94-028) National Cancer Institute National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Environmental Health Sciences INDEX: CANCER; DIABETES, DIGESTIVE, KIDNEY DISEASES; ENVIRONMENTAL HEALTH SCIENCES ONGOING PROGRAM ANNOUNCEMENTS $$INDEX P1 ********************************************************** STENT PATENCY AND STENOSIS IN TIPS (PA-94-090) National Institute of Diabetes and Digestive and Kidney Diseases INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASE $$INDEX P2 ********************************************************** MECHANISMS UNDERLYING SIGN LANGUAGE ACQUISITION AND USE (PA-94-091) National Institute on Deafness and Other Communication Disorders INDEX: DEAFNESS, OTHER COMMUNICATION DISORDERS $$INDEX P3 ********************************************************** NEW INSIGHTS INTO CHRONIC FATIGUE SYNDROME (PA-94-092) National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Mental Health INDEX: ALLERGY, INFECTIOUS DISEASES; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; MENTAL HEALTH ERRATA $$INDEX E1 ********************************************************** NEUROENDOCRINOLOGY OF AGING (PA-94-087) National Institute on Aging National Institute of Diabetes and Digestive and Kidney Diseases INDEX: AGING; DIABETES, DIGESTIVE, KIDNEY DISEASES ATTENTION: The new mailing list for the NIH Guide will be activated in September. Until then, the existing mailing list will be maintained. See INTENT TO MODIFY (NIH Guide, Vol. 23, No. 23, June 17, 1994) for additional information. This publication is available electronically to institutions via BITNET or INTERNET and is also on the NIH GOPHER. Alternative access is through the NIH Grant Line using a personal computer (data line 301/402-2221). Contact Dr. John James at 301/594-7270 for details. THE PUBLIC HEALTH SERVICE (PHS) STRONGLY ENCOURAGES ALL GRANT RECIPIENTS TO PROVIDE A SMOKE-FREE WORKPLACE AND PROMOTE THE NON-USE OF ALL TOBACCO PRODUCTS. THIS IS CONSISTENT WITH THE PHS MISSION TO PROTECT AND ADVANCE THE PHYSICAL AND MENTAL HEALTH OF THE AMERICAN PEOPLE. $$INDEX END ********************************************************* NOTICES OF AVAILABILITY (RFPs AND RFAs) $$R1 BEGIN NHLBI-HV-94-25 ******************************************* INNOVATIVE VENTRICULAR ASSIST SYSTEM NIH GUIDE, Volume 23, Number 29, August 5, 1994 RFP AVAILABLE: NHLBI-HV-94-25 P.T. 34; K.W. 0706040, 0740035, 0705015 National Heart, Lung, and Blood Institute The Bioengineering Section, Heart Program, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) has an interest in encouraging innovation in the development of totally implantable ventricular assist systems that are designed to achieve at least a five-year lifetime with 90 percent reliability. It is anticipated that the proposed systems will incorporate the latest advances in our understanding of circulatory support requirements, materials science, physics and bioengineering, biocompatibility, quality control, and manufacturing. It is expected that this five-year research and development program will be a multi-disciplinary effort and that offerors will include in their proposals theoretical bases for new and improved concepts; mathematical, computer, and physiological modeling; in vitro and animal testing of prototype systems; human fitting studies; evaluation of the biocompatibility of candidate materials; system monitoring; device maintenance; device replacement; environmental issues; and quality control. This solicitation is not intended to support formal device readiness testing nor is it intended to support human subject experimentation. However, the outcome of this program should be the availability of one or more ventricular assist systems that may be considered for future clinical studies. Four to six awards are anticipated. These incrementally funded contracts will be awarded for five years. This is not a Request for Proposals (RFP). RFP NHLBI-HV-94-25 will be released on or about August 3, 1994, with proposals due December 2, 1994. INQUIRIES Written requests must include three self-addressed mailing labels and cite RFP NHLBI-HV-94-25. FAX requests will be accepted. Requests for copies of the RFP are to be sent to: Sharon M. Kraft Contracts Operations Branch National Heart, Lung, and Blood Institute 7550 Wisconsin Avenue MSC 9070 Federal Building, Room 4C04 Bethesda, MD 20892-9070 FAX: (301) 496-9501 $$R1 END ************************************************************ $$R2 BEGIN NICHD-CD-94-13 ******************************************* SYNTHESIS AND TESTING OF NEW ANTIPROGESTATIONAL AGENTS NIH GUIDE, Volume 23, Number 29, August 5, 1994 RFP AVAILABLE: NICHD-CD-94-13 P.T. 34; K.W. 1003006, 1003012, 0750020 National Institute of Child Health and Human Development The Contraceptive Development Branch of the Center for Population Research, National Institute for Child Health and Human Development (NICHD) has a requirement for the synthesis and testing of antiprogestational agents as postcoital antifertility agents. The goals of this acquisition are to design, synthesize, and test antiprogestational agents that are at least ten-fold more potent orally than mifepristone in standard assays for antiprogestational activity in laboratory animals. The selected prototypes for further structural modification may be mifepristone or other leads that have demonstrated oral activity. Such antagonists should, desirably, also have minimal hormonal and other antihormonal activities for use as contraceptive agents. Such antiprogestational agents must also be devoid of effects on central nervous and cardiovascular systems. The Government will carry out in vivo biological assays required to establish the antiprogestational activity of compounds submitted to the Contraceptive Development Branch under the auspices of this acquisition. Offerors must undertake standard in vitro progesterone and glucocorticoid binding assays on all the newly synthesized compounds in house or through subcontracting. Specifically excluded from consideration are (a) inhibitors of progesterone biosynthesis, and (b) estrogens. Organizations must have adequate facilities and capabilities to carry out the proposed synthetic chemical program and in vitro binding assays as mentioned above. The Government estimates the effort to be approximately 4.9 technical person-years annually. The principal investigator must be a synthetic organic and/or medicinal chemist with a Ph.D. degree, who will devote approximately 25 percent of her/his time to the project and must have five years of experience in drug synthesis. All responsible sources may submit a proposal that will be considered by the agency. It is anticipated that four cost- reimbursement incrementally funded type contracts will be awarded as a result of the request for proposals (RFP) for a period of 36 months, beginning June 1, 1995. This announcement is not an RFP. RFP NICHD-CD-94-13 will be available on or about August 19, 1994. Proposals will be due approximately 120 days thereafter. INQUIRIES Requests for copies of the RFP must cite the RFP number and be addressed to: Paul J. Duska Office of Grants and Contracts National Institute of Child Health and Human Development 6100 Building, Room 7A07 Bethesda, MD 20892 FAX: (301) 402-3676 $$R2 END ************************************************************ $$R3 BEGIN HL-94-018 FULL-TEXT ************************************** NHLBI MINORITY TRAINING AND DEVELOPMENT PROGRAMS NIH GUIDE, Volume 23, Number 29, August 5, 1994 RFA AVAILABLE: HL-94-018 P.T. 44, FF; K.W. 0720005, 0715040, 0715032, 0715165 National Heart, Lung, and Blood Institute Application Receipt Date: October 20, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION, FROM THE CONTACTS LISTED IN "INQUIRIES" BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The National Heart, Lung, and Blood Institute (NHLBI) invites grant applications for research training and career development programs directed at developing the research capabilities of minority individuals in areas relevant to cardiovascular, pulmonary, and hematologic diseases and resources. The specific minority research training and development programs encompassed under this RFA include: (1) the Minority Institutional Research Training program; (2) the Minority School Faculty Development Award program; (3) the Short-Term Training for Minority Students program; and, (4) the Research Development Award for Minority Faculty program. The purpose of these programs is to encourage the enhancement of research skills by minority individuals and to increase the number of minority individuals involved in research endeavors in the areas of interest to the NHLBI. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, NHLBI Minority Training and Development Programs, is related to the priority area of heart disease and stroke. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Awards for the programs described in this RFA will be made to domestic U.S. institutions or organizations, including minority institutions, engaged in health related-research in areas related to heart, lung, or blood disorders. Candidates for the career development awards and trainees appointed to the training programs must be either citizens or noncitizen nationals of the United States or have been lawfully admitted to the United States for permanent residence. Individuals on temporary or student visas are not eligible. MECHANISMS OF SUPPORT The mechanisms of support will be the National Institutes of Health (NIH) Institutional National Research Service Award (NRSA) (T32), Short-Term Training grant (T35), and Career Development Award (K14). Responsibility for the planning, direction, and execution of the proposed training and career development programs will be solely that of the applicant. The total project period for an application in response to this RFA may not exceed five years. The anticipated award date is May 1, 1995. Funding beyond the first year of the grant is contingent upon satisfactory progress during the preceding year and the availability of funds. Indirect costs will be awarded based on eight percent of total direct costs exclusive of equipment and tuition and fees. FUNDS AVAILABLE The estimated funds (total costs) available for the first year of support for the entire program is expected to approximate $2 million in fiscal year 1995. The number of awards is estimated to be two awards for Minority Institutional Research Training Program, three awards for the Minority School Faculty Development Award Program, 10 awards for the Short-Term Training for Minority Students Program, and 12 awards for the Research Development Award for Minority Faculty. The actual amounts for the specific mechanisms may vary, depending on the response to the RFA and availability of funds. Funding beyond the first and subsequent years of the grant will be contingent upon satisfactory progress during the preceding years and availability of funds. RESEARCH OBJECTIVES The present RFA is designed to offer research training and career development opportunities for minority individuals and encourage their participation in cardiovascular, pulmonary, and hematologic research. The Minority Research Training and Career Development programs are intended to: o Bolster the participation and research capabilities of minority individuals in research areas relevant to heart, lung, and blood diseases. o Increase the pool of qualified minority investigators pursuing research in heart, blood vessel, lung, and blood disease and transfusion medicine. See the RFA for specific objectives for the individual minority training and development programs. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS Awards for research involving human subjects must follow the "NIH Guidelines On the Inclusion of Women and Minorities as Subjects in Clinical Research." See the RFA for details. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91). Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301-594-7248. Applications must be received by October 20, 1994. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Guidelines and supplemental instructions for each of the specific programs may be obtained from NHLBI staff listed under INQUIRIES. REVIEW CONSIDERATIONS All applications will be reviewed for scientific and technical merit by the Research Training Review Committee of the Division of Extramural Affairs, NHLBI, followed by a second level review by the National Heart, Lung, and Blood Advisory Council. The general review criteria for applications submitted under this RFA are those considered when assessing the merit of career development applications, including the Minority School Faculty Development Award and the Research Development Award for Minority Faculty, or institutional National Research Service Award research training applications, including the Minority Institutional Research Training program and the Short-Term Training for Minority Students program. AWARD CRITERIA Funding decisions will be made on the basis of technical merit of the application as determined by peer review, availability of funds, and program balance among the research areas of the RFA. INQUIRIES Written and telephone requests for this RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA, program guidelines, and supplemental instructions, and inquiries regarding programmatic issues to: John Fakunding, Ph.D. Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute Federal Building, Room 3C04 Bethesda, MD 20892 Telephone: (301) 496-1724 Direct inquiries regarding review issues and mail two copies of the application to: Kathryn Ballard, Ph.D. Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 550 Bethesda, MD 20892 Telephone: (301) 594-7450 Direct inquiries regarding fiscal matters to: Jane Davis Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 4A15C Bethesda, MD 20892 Telephone: (301) 594-7436 Schedule Application Receipt Date: October 20, 1994 Scientific Review Date: December 1994 Advisory Council Date: February 9-10, 1995 Earliest Award Date: May 1, 1995 AUTHORITY AND REGULATION This program is described in the Catalog of Federal Domestic Assistance Numbers 93.837, 93.838, and 93.839. Awards are made under the authority of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 288 and administered under PHS grants policies and Federal Regulations at 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R3 END ************************************************************ $$R4 BEGIN CA-94-028 FULL-TEXT ************************************** MOLECULAR EPIDEMIOLOGY OF PROSTATE CARCINOGENESIS NIH GUIDE, Volume 23, Number 29, August 5, 1994 RFA AVAILABLE: CA-94-028 P.T. 34; K.W. 0785055, 0715035, 0760002 National Cancer Institute National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Environmental Health Sciences Letter of Intent Receipt Date: October 17, 1994 Application Receipt Date: November 23, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION, FROM THE CONTACT LISTED IN "INQUIRIES," BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The Division of Cancer Etiology, National Cancer Institute (NCI); Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and Chemical Exposures and Molecular Biology Branch, National Institute of Environmental Health Sciences (NIEHS) invite investigator-initiated research grant applications for molecular epidemiologic studies to further the understanding of prostate cancer etiology. A major emphasis of this RFA is to stimulate the use of biochemical and molecular markers for identifying and assessing risk factors of prostate cancer, which could lead to effective prevention strategies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Molecular Epidemiology of Prostate Carcinogenesis, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Domestic and foreign, non-profit and for-profit, public and private institutions, and units of local, State, and Federal governments are eligible to apply. Foreign institutions and organizations are not eligible for the First Independent Research Support and Transition (FIRST) (R29) awards. Minority and women investigators are encouraged to apply. MECHANISM OF SUPPORT Support of this program will be through the National Institutes of Health (NIH) individual research project grants (R01), FIRST awards (R29), and competing supplements (S01) to current R01 awards. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for applications submitted in response to the present RFA may not exceed five years. The earliest award date is July 1, 1995. Because the nature and scope of the research proposed may vary, it is anticipated that the size of an average award will vary also ranging from $150,000 to $500,000 in total costs per year. If direct costs exceed $500,000 in any year, the funded study may be considered for an award as a cooperative agreement (U01) (refer to NIH Guide, Vol. 22, Nos. 43 and 45, November 26, and December 17, 1993). Total direct cost award for the five-year R29 grant period may not exceed $350,000 and the direct cost award in any R29 budget period should not exceed $100,000. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary NIH peer review procedure. FUNDS AVAILABLE Approximately $3.75 million ($2,000,000 from NCI, up to $1,000,000 from NIDDK, and $750,000 from NIEHS) in total costs per year for five years will be committed to specifically fund applications which are submitted in response to this RFA. It is anticipated that 8 to 12 awards will be made. Should the NCI, NIDDK, and NIEHS determine that there are sufficient continuing program needs, recipients of awards under this RFA will be invited to submit competing continuation awards. RESEARCH OBJECTIVES The purpose of this RFA is to stimulate innovative molecular epidemiologic research into the origins of prostate cancer, including the biological basis for the striking increase in prostate cancer incidence with age. The types of studies could include, but are not limited to: characterization and validation of biomarkers relevant to prostate carcinogenesis including consideration of variables such as ethnicity, genetic predisposition, diet, and lifestyle; assessment of sex hormonal profiles in body fluids; identification of premalignant lesions; elucidation of the natural history of invasive cancer or progressive stages of the carcinogenic process; exploration of timing of environmental exposures relevant to prostate cancer development; evaluation of micronutrients, macronutrients, xenobiotics and their interactions with hormones and hereditary factors; and clarification of the possible relationships of benign prostatic hyperplasia or chronic prostatitis to prostate cancer. SPECIAL REQUIREMENTS Successful grant awardees under this RFA are strongly encouraged to participate in two, one-day program meetings to be held in Bethesda, Maryland during the second and fifth years of the grant. NIH program staff will coordinate the meetings, which will provide the opportunity for investigators to discuss their work in progress and to consider methodological and scientific issues. The respondents may request sufficient funds within the budget to accommodate expenses for one to two participants at each meeting. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS Awards for research involving human subjects must follow the "NIH Guidelines On the Inclusion of Women and Minorities as Subjects in Clinical Research." See the RFA for details. LETTER OF INTENT Prospective applicants are encouraged to submit, by October 17, 1994, a letter of intent that includes a descriptive title of the proposed research, the name and address of the Principal Investigator, the names of other key personnel, participating institutions, and estimated amount of direct costs if anticipated to exceed $500,000 for any year. Potential applicants for research of this magnitude are encouraged to contact the NCI prior to making detailed plans or submitting their applications. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. The letter of intent is to be sent to Dr. Kumiko Iwamoto at the address listed under INQUIRIES. APPLICATION PROCEDURES Applications are to be received by November 23, 1994, on form PHS 398 (rev. 9/91), available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/594-7248. REVIEW CONSIDERATIONS Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group followed by a second level of review by the National Cancer Advisory Board, the National Advisory Council for Diabetes and Digestive and Kidney Diseases, and the National Advisory Environmental Health Sciences Council. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA, inquiries regarding programmatic issues, and address the letter of intent to: Dr. Kumiko Iwamoto Epidemiology and Biostatistics Program National Cancer Institute 6130 Executive Boulevard, Room 535 Bethesda, MD 20892 Telephone: (301) 496-9600 FAX: (301) 402-4279 Direct inquiries regarding fiscal matters to: Ms. Theresa A. Mercogliano Grants Administration Branch National Cancer Institute Executive Plaza South, Suite 242 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 243 FAX: (301) 496-8601 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.393 and 93.894. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99- 158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R4 END ************************************************************ ONGOING PROGRAM ANNOUNCEMENTS $$P1 BEGIN PA-94-090 ************************************************ STENT PATENCY AND STENOSIS IN TIPS NIH GUIDE, Volume 23, Number 29, August 5, 1994 PA NUMBER: PA-94-090 P.T. 34; K.W. 0715040, 0715115 National Institute of Diabetes and Digestive and Kidney Diseases PURPOSE The purpose of this Program Announcement (PA) is to encourage research on the nonsurgical Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) procedure in the areas of stent patency and stent stenosis. The TIPS procedure has recently become available for the treatment of portal hypertension, variceal bleeding, and ascites. At present the long term effectiveness of TIPS is related to shunt patency and stent stenosis. Studies related to technological advances that improve long term patency as well as studies on stent occlusion and fibrosis are encouraged. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000" a PHS-led national activity for setting priority areas. This PA, Stent Patency and Stenosis in TIPS, is related to the priority area of chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research and Transition (FIRST) (R29) awards. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT The support for this program announcement will be through the NIH research project grant (R01) award and the FIRST (R29) award. Applications seeking support of technological improvements of stents may consider the Small Business Innovation Research (SBIR) program (R43) or the Small Business Technology Transfer (STTR) program (R41) of the NIH, in which the NIDDK participates. For-profit applicants for the SBIR and STTR programs must qualify as a small business concern in accordance with the definition given in the latest edition of the OMNIBUS SOLICITATION OF THE PUBLIC HEALTH SERVICE FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) GRANT AND COOPERATIVE AGREEMENT APPLICATIONS, available from: MTL, Inc., 13687 Baltimore Avenue, Laurel, MD 20707-5096, telephone (301) 206-9385; FAX (301) 206-9722, Internet address: a2y@cu.nih.gov. RESEARCH OBJECTIVES Transjugular intrahepatic porto-systemic shunt has recently become available for the treatment of portal hypertension, variceal bleeding and ascites. The TIPS procedure is highly effective in reducing portal pressure and is thus beneficial in the medical management of patients with acute variceal hemorrhage. However, TIPS is an invasive procedure and is associated with several potential complications. These complications can be categorized according to those relating to transhepatic needle puncture, transvenous access to the portal vein, portal venous cannulation, portosystemic shunting and the stent. At present, long term efficacy is related to shunt patency. For the first year after undergoing the procedure, delayed stenosis or occlusion of the shunt has been reported in 33 to 66 percent of the patients. The pathological process results from either hyperplasia and collagen deposition within the stent or the narrowing of the vascular lumen at the portal venous end of the TIPS stent. New technologies or advances in existing technologies to develop stent materials should be directed to improve long term patency. Further studies to develop research should be directed at elucidating methods to reduce fibrosis and or occlusion of the stent. The latter studies could focus on the role of anticoagulation agents, anti-collagen or fibrotic agents, or anti-inflammatory regimens, such as cytokines, in the maintenance of stent patency. Thus, applications are requested that would improve the technology involving stent patency. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91). Applications will be accepted at the regular application deadlines as indicated in the application kit. The receipt dates for applications for AIDS- related research are found in the PHS 398 instructions. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institute of Health, Westwood Building, Room 449,Bethesda, MD 20992, telephone 301/594- 7248. The title and number of this program announcement must be typed in Section 2a on the face page of the application. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institute of Health Westwood Building Room 240 Bethesda, MD 20892** Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or a Principal Investigator must be included with the application. FIRST Award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST Award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines and will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH in accordance with the standard NIH peer review procedures. Following scientific-technical review, the applications will receive a second-level review by an appropriate National Advisory Council. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the announcement INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Thomas F. Kresina, Ph.D. Division of Digestive Diseases and Nutrition National Institute of Digestive Diseases and Kidney Diseases Westwood Building, Room 3A17 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7578 Direct inquiries regarding fiscal matters to: Ms. Paulette Badman Grants Management Branch National Institute of Digestive Diseases and Kidney Diseases Westwood Building, Room 639 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7543 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.848. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78- 410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$P1 END ************************************************************ $$P2 BEGIN PA-94-091 ************************************************ MECHANISMS UNDERLYING SIGN LANGUAGE ACQUISITION AND USE NIH GUIDE, Volume 23, Number 29, August 5, 1994 PA NUMBER: PA-94-091 P.T. 34; K.W. 0775005, 0410001 National Institute on Deafness and Other Communication Disorders PURPOSE The understanding of the mechanisms by which deaf and hearing individuals acquire and use a manual communication system is limited. Research is needed to determine optimal conditions for such learning, prerequisite abilities for successful acquisition and use of a manual system, as well as the interindividual variations of acquisition of manual communication. The National Institute on Deafness and Other Communication Disorders (NIDCD) encourages applications for the support of studies of the sensory, perceptual, cognitive, neural, and molecular mechanisms underlying acquisition and use of a signed language. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement (PA), Mechanisms Underlying Sign Language Acquisition and Use, is related to the priority area of diabetes and chronic disabling conditions and, special population objectives. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-11474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-11473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Applications from minority individuals, women, and individuals with disabilities are encouraged. MECHANISM OF SUPPORT The support mechanisms for grants in this area will be the individual investigator-initiated research project grant (R01) and the FIRST (R29) award. RESEARCH OBJECTIVES A large proportion of individuals born deaf or who lose their hearing before they acquire spoken language use a form of sign language as their primary mode of communication, either English-language based signing systems or American Sign Language (ASL). Research is needed to increase the understanding of the processes that underlie the acquisition and use of a manual communication system by deaf individuals. Studies concerning the processes and bases of sign language acquisition and use may identify the optimal conditions for learning a manual sign system. This will lead to the development of a model of language that can address the relationship of spoken and signed languages and may also help delineate new methods of successfully introducing and using English with deaf children. Acquisition and processing of signed languages. Language acquisition for deaf children with signing deaf parents typically involves use of American Sign Language (ASL). Previous research, although limited, has indicated that in those individuals exposed to ASL from birth, linguistic competence, on-line sentence processing and underlying neural mechanisms for language may be similar to those found in hearing users of native spoken languages. Additional studies are needed of cognitive, motor, neural, and molecular processes involved in acquisition of ASL among deaf children of deaf parents. A better understanding also is needed of typical patterns of sign language development, and the processes involved in perception and production of sign language in deaf children of hearing parents. Recent evidence suggests that increasing numbers of hearing parents are using sign communication with their deaf children. They commonly use English-based signing, but there is a growing interest in the use of ASL by hearing parents and siblings. There is also a need for additional studies of patterns of acquisition and the cognitive, motor, neural, and molecular processes involved in signing. Recent research findings, concerning the acquisition of ASL by deaf children of hearing parents at various ages beyond infancy, indicate that there is a critical period for the acquisition of ASL, just as there is for the acquisition of spoken languages by hearing individuals. Competency in and efficiency of processing ASL appears to be related to age of exposure to ASL, with a decline in competency and efficiency and possible changes in neural organization for later learners. A full explanation of this phenomenon awaits further investigation. Cognitive, perceptual, and motor processes, and psychosocial issues related to sign language acquisition and use. Acquisition of the ability to employ a signed language depends on the development of a number of interrelated cognitive and linguistic abilities that contribute to the perception and production of sign language. In addition, the nonlinguistic/cognitive outcomes in deaf children exposed to various kinds of sign language are undocumented and warrant investigation. The relation of cognitive and psychosocial development to sign language acquisition and use requires further investigation. Sign language production makes use of space and movement; thus the perception of sign language requires the processing of complex arrays of dynamic motion. Investigations are needed of sign language perception, particularly the processing of motion and form and how such visual-dynamic information is processed linguistically. Comparison of the processes of spoken language perception and signed language perception in hearing and deaf individuals provides a unique means of determining those aspects of language that are independent of the modality (signed or spoken) of communication. Neural underpinnings of sign language acquisition and use. The interface of sign language acquisition to other biological phenomena is important to our understanding of brain-behavior relationships. Electrophysiologic findings indicate that, in spite of the very different input/output systems employed, the same or similar areas in the left hemisphere of the brain are involved in language tasks in native ASL signers as in speakers of English. However, studies of this type, examining the organization of the brain and its relation to sign language acquisition and use, are limited. Studies of brain mapping of sign language function are needed, as are continued investigations of differences and similarities in the way the brain processes spoken and signed languages. Questions remain concerning the ways in which cortical organization may be influenced by age of acquisition and by early perceptual and linguistic experience. Examples of issues to be addressed in applications submitted in response to this Program Announcement include, but are not limited to, the following: o The acquisition of ASL or other signing systems in children exposed to these languages from birth as well as in children whose access to a first natural language is delayed or incomplete; o The relation between cognitive and psychosocial development and the acquisition of ASL in deaf children of deaf parents and in deaf children of hearing parents; o The relation of infants' early acquisition of sign language phonology, assessed through tests of sign perception, to the acquisition of other levels of a signed language, such as the acquisition of signs (lexicon), sign meanings (semantics) and grammatical constructions (syntax); o The underlying perceptual and motor processes in sign language, for example, basic and higher level processes underlying the perception and use of space, form and movement in sign language; o The nature of parallel processing of simultaneous visual and auditory information in deaf children and adults; o Identification and characterization of the neural systems that underlie the representation, perception and production of signed languages in both adults and children using, when appropriate, techniques such as measuring event-related potentials and imaging technology; o The specialization of the cerebral hemispheres for language and other types of cognitive processing in deaf individuals, including the ways in which the neural organization and function of the basic sensory systems may be changed by deafness and/or by acquisition of sign language; o Critical periods for the natural acquisition of signed languages, and the effects of delayed exposure to spoken or signed language on the development of linguistic competence and cognitive and academic abilities. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 18, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the standard application deadlines as indicated in the application kit. These kits are available from most institutional offices of sponsored research; the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7248; and the NIDCD Program Administrator listed under INQUIRIES. The title and number of the program announcement must be typed in Section 2a on the face page of the application. Applications for the FIRST Award (R29) must include at least three sealed letters of reference attached to the face page of the original application. FIRST Award (R29) applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit by an appropriate Initial Review Group within the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. Following scientific/technical review, the applications will receive a second-level review by the appropriate national advisory council. AWARD CRITERIA Applications will compete for available funds with all other approved applications assigned to that ICD. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review. o Availability of funds. o Program priorities among research areas of the announcement. INQUIRIES Written and telephone inquiries concerning this PA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Judith A. Cooper, Ph.D. Division of Communication Sciences and Disorders National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400-C 6120 Executive Boulevard Rockville, MD 20892 Telephone: (301) 496-5061 FAX: (301) 402-6251 Direct inquiries regarding fiscal matters to: Sharon Hunt Grants Management Office National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400-B 6120 Executive Boulevard Rockville, MD 20892 Telephone: (301) 402-0909 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.173. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$P2 END ************************************************************ $$P3 BEGIN PA-94-092 ************************************************ NEW INSIGHTS INTO CHRONIC FATIGUE SYNDROME NIH GUIDE, Volume 23, Number 29, August 5, 1994 PA NUMBER: PA-94-092 P.T. 34; K.W. 0715043 National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Mental Health PURPOSE The National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and National Institute of Mental Health (NIMH) invite investigator-initiated research grant applications to support research on the etiology, natural history, and pathogenesis of chronic fatigue syndrome (CFS). HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This program announcement, New Insights into Chronic Fatigue Syndrome, is related to the priority area of chronic disabling diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-0325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications from minority individuals and women are encouraged. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. MECHANISM OF SUPPORT Traditional research project grant (R01) and FIRST award (R29) applications may be submitted in response to this program announcement. The R01 mechanism can be used to support small studies. Funds and time requested should be appropriate for the research proposed. RESEARCH OBJECTIVES Background Chronic fatigue syndrome (CFS) is a multisystem syndrome thought to be triggered by acute infectious illness and characterized by months of debilitating fatigue frequently associated with myalgia, headache, sore throat, low grade fever, cognitive complaints, gastrointestinal symptoms, and tender lymph nodes. There have been reports of immunologic and, more recently, neuroendocrine parameters that differ in CFS patients as a group compared to healthy controls. However, no single marker has been identified that can be used to diagnose the syndrome. CFS is diagnosed three to four times more frequently in women than in men and about 10 times more often in white Americans than in other American population groups. The cause and pathogenic mechanisms of the illness are unknown. Research Objectives and Experimental Approaches Well-designed studies are needed to provide a better understanding of CFS and to develop diagnostic and intervention strategies. Studies should include appropriate sample sizes and test biologically rational hypotheses concerning etiology, natural history or pathogenesis of the syndrome. Applications for small studies that explore new ideas are also encouraged and could provide the basis for submission of a subsequent larger grant application. Clinical epidemiologic studies may identify factors that affect prognosis or that are associated with susceptibility, including immunogenetic, behavioral, environmental, and psychosocial factors. Several observations reported in the literature merit further study to determine their biologic and/or epidemiologic basis, generalizability and/or role in CFS. These include, but are not limited to: o lymphocyte patterns suggestive of immune activation (e.g., alterations in T-cell subsets number and function, altered cytokine levels and function) o low levels of cortisol and corticotropin-releasing hormone in CFS patients in the absence of documented adrenal-hypothalamic axis dysfunction attributable to other causes o increased frequency of sleep disturbances (hypersomnia or insomnia) o overlapping symptomatology with fibromyalgia o low tolerance to physical exertion manifested by prolonged generalized fatigue after very moderate exercise o demographic risk factors (gender, age, race, socioeconomic class) o reactivation of latent viruses (e.g., use of sensitive and specific assays to measure viral reactivation in carefully defined and controlled specimens) o increased frequency of psychiatric diagnoses in CFS patients (except those that would exclude an individual from the CFS case definition) o increased frequency of atopy in CFS patients compared with the U.S. population as a whole o highly active lifestyle prior to onset of CFS Multidisciplinary studies and collaboration among investigators with expertise in appropriate disciplines are encouraged. When investigators are at different institutions, individual R01 applications may include consortium arrangements. Collaborative arrangements with on-going studies that provide patient populations, specimens and data are encouraged. Such arrangements should be clearly delineated in the application. The methodologies and personnel involved in statistical/epidemiological analyses should be described in the application and evident in the study design. The hypothesis(es) to be tested should be clearly stated. The constructs and measurements to be used operationally to obtain statistically and biologically meaningful results should be clearly defined and enumerated. The value of studies of patients or their specimens will be directly related to the care exercised in selection and initial characterization of cases and controls. A detailed description of case recruitment procedures, the criteria to be used for case definition and the manner in which the criteria are to be applied must be included. Similar care should be given to descriptions of enrollment of comparison groups. Investigators are encouraged to use the CFS case definition as initially presented in Holmes, et al. (Annals of Internal Medicine: 108, 387-389, 1988) and subsequently modified in Schluederberg, et al. (Annals of Internal Medicine: 117, 325-331, 1992) and in Fukuda, et al (in press). If other case definitions are proposed, they should be clearly defined and the rationale for their choice clearly delineated. Parameter Measurements Applications to estimate the frequency of physiological or behavioral variables or responses or to address other quantitative aspects in relevant populations should pay particular attention to sample sizes required to attain the degree of precision sought or needed for statistically and biologically meaningful results. The reliability and validity of markers chosen for measurement should be demonstrated. Applications attempting to examine interrelationships among two or more separate factors are encouraged to the extent that the types and numbers of subjects are sufficient for such comparisons. The measurement of cellular phenotypes, cytokine activities and other immunological and viral markers are highly dependent on the assay system chosen and its execution. Thus, it is very important that applicants clearly define the methodologies to be used, the rationale for choosing that methodology and for validating results as well as methods of collection, processing, and storage of samples. When conflicting results have been reported in the literature, applicants should provide possible explanations for such variability and indicate how their approach might resolve the issue. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research", which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23, Number 11. Investigators may obtain copies from these sources or from the program staff or contact persons listed below. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted on the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7248. Each application must be identified by checking "YES" on line 2a of the PHS face page, and the number and title of this announcement must be typed in section 2a. FIRST (R29) applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The completed original and five legible, single-sided copies of the application must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the Center as a resource for conducting the proposed research. If so, a letter of agreement from the GCRC Program Director must be included in the application material. REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. Following scientific/technical review, the applications will receive secondary review by the appropriate national advisory council. AWARD CRITERIA Applications will compete for available funds with all other favorably recommended applications assigned to that ICD. The following will be considered when making funding decisions: quality of the proposed project as determined by peer review, program balance among research areas of the announcement, availability of funds. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Susan Spring, Ph.D. Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases Solar Building, Room 3A14 6003 Executive Boulevard MSC 7630 Bethesda, MD 20892-7630 Telephone: (301) 496-7453 FAX: (301) 496-8030 Susana A. Serrate-Sztein, Ph.D Arthritis Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 405 Bethesda, MD 20892 Telephone: (301) 594-9953 FAX: (301) 594-9673 Fred Altman, Ph.D. Basic Prevention and Behavioral Medicine Research Branch National Institute of Mental Health Parklawn Building, Room 11C06 Rockville, MD 20857 Telephone: (301) 443-4337 FAX: (301) 443-4822 Direct inquiries regarding fiscal matters to: Ms. Victoria Putprush Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Building, Room 4B35 6003 Executive Boulevard MSC 7610 Bethesda, MD 20892-7610 Telephone: (301) 496-7075 FAX: (301) 480-3780 Mr. Joseph L. Brown Grants Management Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 722C Bethesda, MD 20892 Telephone: (301) 594-9970 FAX: (301) 594-9950 Mr. Bruce Ringler Grants Management Branch National Institute of Mental Health Parklawn Building, Room 7C08 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-3065 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.856, Microbiology and Infectious Disease Research, No. 93.846, Arthritis, Musculoskeletal, and Skin Diseases Research and No. 93.242, Mental Health Research. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grant policies and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$P3 END ************************************************************ ERRATA $$E1 BEGIN P2 19940729 APPEND PA-94-087 BOTH *************************** NEUROENDOCRINOLOGY OF AGING NIH GUIDE, Volume 23, Number 29, August 5, 1994 PA NUMBER: PA-94-087 P.T. 34; K.W. 0710010, 0785105 National Institute on Aging National Institute of Diabetes and Digestive and Kidney Diseases The following correction is issued for PA-94-087, which was published in the NIH Guide, Vol. 23, No. 28, July 29, 1994. The second sentence under MECHANISM OF SUPPORT should read: Foreign institutions are NOT eligible for FIRST (R29) awards. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Andrew A. Monjan, Ph.D., M.P.H. Neuroscience and Neuropsychology of Aging Program National Institute on Aging Gateway Building, Suite 3C307 Bethesda, MD 20892 Telephone: (301) 496-9350 FAX: (301) 496-1494 $$E1 END ************************************************************ From owner-sci-resources@net.bio.net Wed Aug 03 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA HL-94-018 - V23(29) 08/05/94 Date: 4 Aug 1994 13:35:14 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 595 Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <31rje2$10q@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA HL94018 HL-94-018 P1O1 *************************************** NHLBI MINORITY TRAINING AND DEVELOPMENT PROGRAMS NIH GUIDE, Volume 23, Number 29, August 5, 1994 RFA: HL-94-018 P.T. 44, FF; K.W. 0720005, 0715040, 0715032, 0715165 National Heart, Lung, and Blood Institute Application Receipt Date: October 20, 1994 PURPOSE The National Heart, Lung, and Blood Institute (NHLBI) invites grant applications for research training and career development programs directed at developing the research capabilities of minority individuals in areas relevant to cardiovascular, pulmonary, and hematologic* diseases and resources. The specific minority research training and development programs encompassed under this request for applications (RFA) include: (1) the Minority Institutional Research Training program; (2) the Minority School Faculty Development Award program; (3) the Short-Term Training for Minority Students program; and, (4) the Research Development Award for Minority Faculty program. The purpose of these programs is to encourage the enhancement of research skills by minority individuals and to increase the number of minority individuals involved in research endeavors in the areas of interest to the NHLBI. * Within NHLBI, the term "hematologic" means research on thrombosis and hemostasis, immunohematology, blood cell disorders, hematopoiesis, thalassemia, sickle cell disease, transfusion medicine, blood resources including blood component and derivative therapy, blood substitutes and blood resource management, aspects of AIDS-products in AIDS prevention and treatment, and AIDS-related bone marrow and hematologic disorders. Other Institutes of the NIH are responsible for research on disorders of white cells, including the leukemias and other blood malignancies, and basic immunology related to the lymphoid system. Therefore, NHLBI cannot provide support for such studies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, NHLBI Minority Training and Development Programs, is related to the priority area of heart disease and stroke. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 telephone 202-783-3238. ELIGIBILITY REQUIREMENTS Awards for the programs described in this RFA will be made to domestic U.S. institutions or organizations, including minority institutions, engaged in health related-research in areas related to heart, lung, or blood disorders. Candidates for the career development awards and trainees appointed to the training programs must be either citizens or noncitizen nationals of the United States or have been lawfully admitted to the United States for permanent residence. Individuals on temporary or student visas are not eligible. Individual eligibility requirements for the specific grant awards listed above are as follows: Minority Institutional Research Training Program (T32). Awards in this program will be made to domestic minority institutions, each of which will collaborate with a research center that has well-established cardiovascular, pulmonary, or hematologic research and research training programs. A minority school is defined as a domestic medical or non-medical college, university or equivalent school in which students of minority ethnic groups including Blacks, Hispanics, American Indians, Asians, or Pacific Islanders comprise a majority of the school's enrollment. The program director at the minority school will be responsible for the selection and appointment of trainees and the overall direction of the training program. Trainees appointed to the program will be placed with a mentor who is an accomplished investigator at the cooperating research center and who will assist the advisor at the minority institution in the trainee's development and research plan. Trainees must: (1) be training at the post-baccalaureate level (i.e., predoctoral level) in a relevant biomedical or behavioral science and have made a strong commitment to completing a doctoral degree, (2) be enrolled in a minority health professional school, or (3) have a doctoral degree or equivalent in a biomedical or behavioral science (i.e., postdoctoral level). The collaborating research center should be a university, medical school, or comparable institution that has strong, well-established research and research training programs in areas relevant to heart, lung, and blood diseases. Cooperation between institutions is needed to provide each trainee with a mentor who is recognized as an accomplished investigator in cardiovascular, pulmonary, or hematologic research and who will assist the advisor at the minority institution in the trainee's development and research plan. Minority School Faculty Development Award Program (K14). Awards in this program will be made to domestic minority institutions on behalf of individuals, each of whom will work with a mentor at a nearby (within 100 miles) research center. The mentor must be recognized as an accomplished investigator in the area proposed and must provide guidance for the awardee's development and research plan in research areas related to heart, lung, or blood disorders. The commitment of the institution to the faculty candidate's research and development must clearly be presented in the application. This must include statement(s) from the Dean and departmental chair indicating that the candidate will be provided with sufficient release time from other duties to accomplish the research goals stated in the application. Candidates for this award are minority school faculty members who: (1) are citizens of the United States, non-citizen nationals, or permanent residents at the time of application, (2) have a doctoral degree or equivalent in a biomedical or behavioral science, (3) wish to receive specialized training in cardiovascular, pulmonary, or hematologic research, and (4) have the background and potential to benefit from the training. Each candidate must identify and complete arrangements with a nearby mentor (within approximately 100 miles) who is recognized as an accomplished investigator in the research area proposed and who will provide guidance for the awardee's development and research plan. Plans for the intensive training during the summer period (two to three months) as well as during the academic years must be developed with the mentor. Short-Term Training for Minority Students Program (T35). Awards in this program will be made to domestic institutions or organizations, including minority institutions, engaged in research in areas related to heart, lung, or blood disorders. These grants will support short-term research training experiences of two to three months duration for minority undergraduate students, minority students in health professional schools, and minority graduate students. The grantee institution will be responsible for the selection and appointment of trainees. Special attention should be given to the recruitment of individuals from minority groups that are underrepresented nationally in the biomedical and behavioral sciences, i.e., Blacks, Hispanics, Native Americans, Alaska Natives, and Pacific Islanders. Trainees must have successfully completed at least one undergraduate year at an accredited school or university or have successfully completed one semester at a school of medicine, optometry, osteopathy, dentistry, veterinary medicine, pharmacy or public health, or an institution with an accredited graduate program, prior to participating in the program. Trainees appointed to the program need not be from the grantee institution, but may include a number of minority students from other institutions, schools, colleges, or universities. These grants are intended to introduce students to research that would not otherwise be available through their regular course of studies. For graduate students, this may include graduate students in programs, such as mathematics, where they would not normally be exposed to biomedical research or graduate students who may need a specialized research experience to supplement their normal graduate education. Individuals holding Ph.D., M.D., D.V.M., or equivalent doctoral degrees in the health sciences are not eligible. Research Development Award for Minority Faculty (K14). Awards in this program will be made to domestic institutions or organizations, including minority institutions, on behalf of individuals. Individuals applying for this program must have been awarded a doctoral degree (Ph.D., M.D., D.V.M., D.O. degree or its equivalent), have a faculty appointment at an accredited college or university at the time of award, and be members of an underrepresented minority group. For the purpose of this program, underrepresented minority faculty members are defined as individuals belonging to a particular ethnic or racial group that has been determined by the grantee institution to be underrepresented in biomedical or behavioral research. In making grant awards under this program, the NHLBI will give priority to projects involving Black, Hispanic, Native American, Pacific Islander, and other ethnic or racial group members who have been found to be underrepresented in biomedical or behavioral research nationally. Candidates must be nominated by an institution on the basis of qualifications, interests, accomplishments, motivation, and potential for performing quality research. The candidate's academic background, previous experience, and career goals should determine both the necessary length and the kind of program that is appropriate. Each candidate must identify a sponsor(s) who is an accomplished investigator in the research area proposed, who is engaged in research in areas related to heart, lung, or blood disorders, and has experience in developing independent investigators. The sponsor is not required to be affiliated with the applicant institution. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) National Research Service Award (NRSA) Institutional research training grant (T32), Short-Term Training grant (T35), and Career Development Award (K14). Responsibility for the planning, direction, and execution of the proposed training and career development programs will be solely that of the applicant. The total project period for an application in response to this RFA may not exceed five years. The anticipated award date is May 1, 1995. Funding beyond the first year of the grant is contingent upon satisfactory progress during the preceding year and the availability of funds. Indirect costs will be awarded based on eight percent of total direct costs exclusive of equipment and tuition and fees. Specific characteristics of each program are as follows: Minority Institutional Research Training Program (T32). Minority Institutional NRSA Research Training programs may support predoctoral, postdoctoral, and short-term trainees in health professional schools. The stipend level for predoctoral and short-term trainees is $10,008 per year, and stipend levels for postdoctoral trainees range from $19,608 to $32,300 per year. Stipends may be supplemented from non-Federal sources. Training related expenses ($1,500 annually for predoctoral trainees and $2,500 annually for postdoctoral trainees), tuition and fees, and travel expenses ($800 per trip) may also be requested for trainees, although the levels may vary depending on the type of training to be supported. The trainees may be appointed for 9 to 12 months (for short-term trainees, the period of appointment may be of 2 to 3 months duration) at any time during the course of the budget period after acceptance as a full-time student. A strong interest in a cardiovascular, pulmonary, or hematologic research career must be evident. Minority School Faculty Development Award Program (K14). The awardee may receive salary support up to a maximum of $50,000 per year plus fringe benefits for five years. All funds must be used to support the awardee. Awardees must commit 100 percent effort during the summer and/or off quarter periods and at least 25 percent effort during the academic year. In addition to the salary requested for the candidate, support for up to 10 percent of the mentor's salary during the summer experience may also be requested. Up to $20,000 per year will be provided for research support. Details regarding the apportionment of these funds between the minority institution and the research center must be worked out with the mentor at the research center and agreed to by representatives of both institutions. If funds are to be transferred to the mentor's institution for any purpose, arrangements for the transfer or conduct of activities should be formalized in a contract or written agreement with the mentor's institution and submitted as part of the application. The award is non-renewable and may not be transferred to another institution or another faculty member. The indirect cost rate on subcontract costs for the mentor's institution may not exceed eight percent of total costs. Short-Term Training for Minority Students Program (T35). Institutions may request support for short-term training programs for at least four and not more than 24 trainees per year. Trainees may be minority undergraduate, graduate, or health professional students. The stipend level for trainees is $834 per month. Stipends may be supplemented from non-federal funds. Training-related expenses up to $125 per month per trainee may be requested. In addition, up to $500 per trainee may be requested to cover domestic travel to and from the training site and up to $250 per month per trainee may be requested to cover the cost of housing at the training site. Trainee tuition and fees, where necessary to the research training, must be covered by the Training Related Expenses. Research Development Award for Minority Faculty (K14). The awardee may receive salary support up to a maximum of $50,000 plus fringe benefits per year for five years. All funds must be used to support the awardee. A minimum of 80 percent effort must be devoted to the research program. The remainder may be devoted to other teaching, clinical, or administrative pursuits that are consistent with the program goals, i.e., the candidate's development into an independent biomedical scientist or the maintenance of the teaching and clinical skills needed for an academic research career. In addition to the salary request for the candidate, support for up to five percent of the sponsor's salary may be requested. Up to $30,000 per year will be provided for research support. Substitution of another sponsor and/or a change of institution may be permitted with the prior approval of the NHLBI. FUNDS AVAILABLE The estimated funds (total costs) available for the first year of support for the entire program is expected to be approximately $2 million in fiscal year 1995. The actual amounts for the specific mechanisms may vary, depending on the response to the RFA and availability of funds, but the anticipated number of awards for each mechanism is as follows: Minority Institutional Research Training Program: 2 new awards Minority School Faculty Development Award Program: 3 new awards Short-Term Training for Minority Students Program: 10 new awards Research Development Award for Minority Faculty: 12 new awards RESEARCH OBJECTIVES Many studies have emphasized the need for minority individuals to participate in modern research activities to develop their investigative talents. Whereas approximately 12 percent of the U.S. population is Black, less than 0.25 percent of individuals holding a Ph.D. degree in biomedical science are Black. Furthermore, the number of doctorates, both M.D.s and Ph.D.s, awarded to other ethnic minority groups, such as Native Americans or Hispanics, is proportionally lower than for Blacks. There are existing programs at the NIH that are designed to answer this need. These include the Minority Biomedical Research Support Program, the Minority Access to Research Careers Program, and the Minority Research Supplements Program. Even though these programs appear successful in meeting their specific objectives and career development goals, minority graduate students, health professional students, and postdoctoral students in minority schools need further opportunities to develop biomedical and behavioral research skills and become productive investigators. While there is strong interest in the scientific community in attracting minority students into research careers, few minority students opt for science degrees and research careers, and few minority graduates of health professional schools go on to investigative careers. The shortage of qualified minority investigators in academic research positions may even exacerbate the situation due to a lack of visible role models for students. One method of addressing this problem is by attracting minority students to research opportunities and by providing them with research training to develop their research capabilities in cardiovascular, pulmonary, and hematologic disease areas. In addition, by increasing the research capabilities of minority faculty members and faculty members at minority institutions, these individuals may serve as role models for minority undergraduate and graduate students, and stimulate these students to become more cognizant of research opportunities in cardiovascular, pulmonary, and hematologic disease areas. The present RFA is designed to offer research training and career development opportunities for minority individuals and encourage their participation in cardiovascular, pulmonary, and hematologic research. The Minority Research Training and Career Development programs are intended to: o Bolster the participation and research capabilities of minority individuals in research areas relevant to heart, lung, and blood diseases. o Increase the pool of qualified minority investigators pursuing research in heart, blood vessel, lung, and blood disease and transfusion medicine. Specific objectives for the individual programs are as follows: The Minority Institutional Research Training Program is intended to: o Train graduate students, health professional students, and postdoctoral students at minority schools that have the potential to develop a meritorious program in cardiovascular, pulmonary, or hematologic research for research careers in areas relevant to these diseases. o Stimulate cardiovascular, pulmonary, and hematologic diseases and hematologic resources research, prevention, control, and education by offering minority school graduate students, health professional students, and postdoctoral students the opportunity to enhance their research capabilities in these areas. The Minority School Faculty Development Award is intended to: o Encourage the development of faculty investigators at minority schools in areas relevant to cardiovascular, pulmonary, and hematologic diseases and transfusion medicine. o Stimulate cardiovascular, pulmonary, and hematologic disease research, prevention, control, and education by offering minority school faculty members the opportunity to enhance their research capabilities in these areas. The Short-Term Training for Minority Students program is intended to: o Provide minority undergraduate students, graduate students, and students in health professional schools exposure to opportunities inherent in research careers in areas relevant to cardiovascular, pulmonary, and hematologic diseases. o Attract highly qualified minority students into biomedical and behavioral research careers and increase the already short supply of minority investigators. The Research Development Award for Minority Faculty is intended to: o Encourage research-oriented minority faculty to develop independent research skills and gain experience in advanced methods and experimental approaches in the basic and applied sciences relevant to heart, blood vessel, lung, and blood diseases and transfusion medicine. o Increase the pool of highly trained minority investigators who can use advanced technologies to address the major problems in heart, blood vessel, lung, blood diseases, and transfusion medicine. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91). Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301-594-7248. Guidelines and supplemental instructions for each of the specific programs may be obtained from NHLBI staff listed under INQUIRIES. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** Two additional copies of the application must be sent to: Scientific Review Administrator NHLBI Research Training Review Committee National Heart, Lung, and Blood Institute Westwood Building, Room 550 Bethesda, MD 20892 Telephone: (301) 594-7450 Applications must be received by October 20, 1994. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS All applications will be reviewed for scientific and technical merit by the Research Training Review Committee of the Division of Extramural Affairs, NHLBI, followed by a second level review by the National Heart, Lung, and Blood Advisory Council. The following criteria will be considered when assessing the merit of career development applications, including the Minority School Faculty Development Award and the Research Development Award for Minority Faculty. o Candidate -- The candidate's overall competence as demonstrated by academic record and performance, potential for a career in independent research, and commitment or interest in pursuing an academic research career. o Sponsor(s) -- The sponsor's accomplishments in the scientific research area(s) proposed, experience and track record in training investigators, and commitment for the duration of a candidate's research development. o Environment -- The applicant institution's ability to provide adequate facilities, resources, and opportunities necessary for the candidate's training, and the institutional commitment to the candidate. If different from the applicant institution, the quality and extent of interaction of the faculty in the basic and clinical sciences, and the quality of the research and research training programs at the sponsor's institution. o Career Development Plan -- The adequacy of the research career development plan, based on the candidate's past research experience, training, and career goals. o Research Project -- Scientific merit of the proposed research project and its appropriateness as a vehicle for developing the candidate's research skills. o If applicable, adequacy of adherence to NIH policy concerning the inclusion of women and minorities in clinical research study populations. The following criteria will be considered when assessing the merit of a research training grant application, including the Minority Institutional Research Training program and the Short-Term Training for Minority Students program. o Adequacy of faculty, facilities, and resources for the proposed research training; o Commitment of the relevant faculty and the institution to the goals of the training program and the caliber of preceptors as researchers including successful competition for research support; o Past research training record for the program director and designated preceptors in terms of the success of trainees pursuing research activities; o Objectives, design, and direction of the research training program. AWARD CRITERIA The following will be considered in making funding decisions: o Technical merit of the application as determined by peer review o Availability of funds o Program balance among the research areas of the announcement INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding program guidelines, supplemental instructions, or programmatic issues to: John Fakunding, Ph.D. Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute Federal Building, Room 3C04 Bethesda, MD 20892 Telephone: (301) 496-1724 LeeAnn Jensen, Ph.D. Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute Federal Building, Room 5C04 Bethesda, MD 20892 Telephone: (301) 496-8387 Mary Reilly, M.S. Division of Lung Diseases National Heart, Lung, and Blood Institute Westwood Building, Room 640A Bethesda, MD 20892 Telephone: (301) 594-7466 Thomas Blaszkowski, Ph.D. Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute Federal Building, Room 208A Bethesda, MD 20892 Telephone: (301) 496-1841 James P. Kiley, Ph.D. National Center for Sleep Disorders Research National Heart, Lung, and Blood Institute Building 31, Room 4A11 Bethesda, MD 20892 Telephone: (301) 496-7443 Direct inquiries regarding fiscal matters to: Jane Davis Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 4A15C Bethesda, MD 20892 Telephone: (301) 594-7436 AUTHORITY AND REGULATION This program is described in the Catalog of Federal Domestic Assistance numbers 93.837, 93.838, and 93.839. Awards are made under the authority of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 288) and administered under PHS grant policies and Federal Regulations at 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service (PHS) strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Wed Aug 03 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA CA-94-028 - V23(29) 08/05/94 Date: 4 Aug 1994 13:35:20 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 581 Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <31rje8$113@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA CA94028 CA-94-028 P1O1 *************************************** MOLECULAR EPIDEMIOLOGY OF PROSTATE CARCINOGENESIS NIH GUIDE, Volume 23, Number 29, August 5, 1994 RFA: CA-94-028 P.T. 34; K.W. 0785055, 0715035, 0760002 National Cancer Institute National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Environmental Health Sciences Letter of Intent Receipt Date: October 17, 1994 Application Receipt Date: November 23, 1994 PURPOSE The Division of Cancer Etiology, National Cancer Institute (NCI); Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Chemical Exposures and Molecular Biology Branch, National Institute of Environmental Health Sciences (NIEHS) invite investigator-initiated research grant applications for molecular epidemiologic studies to further the understanding of prostate cancer etiology. The purpose of this initiative is to stimulate the use of biochemical and molecular markers for identifying and assessing risk factors, which could lead to effective prevention strategies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Molecular Epidemiology of Prostate Carcinogenesis, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone 202-783-3238. ELIGIBILITY REQUIREMENTS Domestic and foreign, non-profit and for-profit, public and private institutions, such as colleges, universities, hospitals, research laboratories, units of State and local governments, and agencies of the Federal government are eligible to apply. Foreign institutions and organizations are not eligible for the First Independent Research Support and Transition (FIRST) awards (R29) but may submit applications for individual research project grants (R01); foreign applicants may also participate in laboratory or clinical programs through subcontract or consortium arrangements. Minority and women investigators are encouraged to apply. MECHANISM OF SUPPORT Support of this program will be through the National Institutes of Health (NIH) individual research project grants (R01), FIRST awards (R29), and competing supplements (S01) to current R01 awards. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary NIH peer review procedures. However, should the NCI, NIDDK, and NIEHS determine that there are sufficient continuing program needs, recipients of awards under this RFA will be invited to submit competing continuation applications for review. It is anticipated that the size of an award will vary due to the nature and scope of the proposed research with the average R01 award ranging from $150,000 to $500,000 per year in total costs. If direct costs exceed $500,000 in any year, the funded study may be considered for an award as a cooperative agreement (U01) (refer to NIH Guide, Vol. 22, No. 43, November 26, 1993 and Vol. 22, No. 45, December 17, 1993). The total project period for applications may not exceed five years. The total direct cost award for the five-year R29 grant period may not exceed $350,000 and the direct cost award in any R29 budget period may not exceed $100,000. The earliest feasible start date for the initial awards will be July 1, 1995. FUNDS AVAILABLE Approximately $3.75 million ($2,000,000 from NCI, up to $1,000,000 from NIDDK and $750,000 from NIEHS) in total costs per year for five years will be committed specifically to fund applications that are submitted in response to this RFA. It is anticipated that 8 to 12 awards will be made. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in financial plans of the NCI, NIDDK, and NIEHS, the award of grants pursuant to this RFA is contingent upon the availability of funds at the time the awards are made. RESEARCH OBJECTIVES Background In the United States, prostate cancer has become the most frequently diagnosed neoplasm and the second leading cause of cancer mortality in men after lung cancer. Its incidence rate has continued to increase rapidly during the past two decades, especially in men over the age of 50 years, and 165,000 new incident cases comprising 27 percent of male cancers were expected to be diagnosed in 1993 (1). Prostate cancer develops more rapidly with advancing age than any other form of cancer and since the population is aging, its impact is a major public health concern. The etiology of prostate cancer is obscure. Clues may be derived from descriptive epidemiology characterizing the steep slope of incidence in the elderly, variation in race-specific and international incidence patterns, and high prevalence of latent (histologically apparent and clinically silent) carcinoma. The most compelling hypothesis supports a hormonal etiology based on the androgen-dependency of the prostate gland for growth and function. Studies in animal models have demonstrated the role of androgens in the induction of prostate cancer. Moreover, in humans, men castrated before puberty do not develop prostate cancer, and prostate cancer has responded to estrogen therapy (2). Case-control studies of serum testosterone and other hormones have thus far, however, reported inconsistent results (3), although it has been reported that populations with low levels of serum androgens have a lower incidence of prostate cancer (4). Although studies of familial aggregation and genetic analyses have indicated a heritable component in risk (5), the wide geographic variation in rates as well as migrant studies suggest a role for environmental factors, including diet and nutrition. African-American men have the highest incidence and mortality rates in the world, two-fold higher than among U.S. whites and much higher than among African populations. The incidence varies widely around the world: a 50-fold difference exists between countries with the highest (blacks in Detroit, Michigan: 91.1 per 100,000) and lowest (Shanghai, China: 1.8 per 100,000) incidence rates of prostate cancer (6). In addition, immigrants from low-risk countries (e.g., China or Japan) experience an increased risk after migrating to a high-risk country (e.g., United States). Evidence from case- control and cohort studies has suggested that dietary fat may be associated with invasive prostate cancer (7-9) while certain micronutrients such as vitamin D may be protective (10). The role of other environmental exposures (e.g., occupation, ionizing radiation, viruses) and the effects of lifestyle factors (e.g., smoking, alcohol consumption, sexual behavior, vasectomy) have yet to be clarified. The special characteristic of latent prostatic tumors, detected most often at autopsy and estimated to affect one third of all males older than 50 years, has remained an enigma in the understanding of the natural history and biology of invasive prostate cancer. Interestingly, there are no clear racial or geographic differences in the occurrence of small intraprostatic foci of latent cancer, whereas the prevalence of larger focal lesions parallels the variations in mortality rates. It has been hypothesized that environmental factors may affect the transition of latent to invasive cancer by acting as tumor promoters (11). Little is known about the molecular events and processes involved in the progressive transition to invasive cancer. To date, genetic alterations in chromosomes 5q, 8p, 10q, 16p, and 17p have been reported in relation to prostate carcinogenesis (12, 13). An advisory workshop was organized and sponsored by the NCI and co-sponsored by the National Institute on Aging (NIA), NIDDK, and NIEHS in Bethesda, Maryland, on September 27, 1993. The objective was to determine the status of laboratory technology for endocrine biomarkers and to identify directions for advancing molecular epidemiologic research in the etiology of prostate cancer. The power of molecular epidemiology studies, which incorporate laboratory advances in molecular biology, genetics and biochemistry with epidemiologic study designs, was emphasized. Workshop recommendations identified research needs in the following general areas: (a) methodological considerations in the measurement of hormonal profiles (e.g., androgen and androgen metabolites) in body fluids; (b) studies of androgen metabolism in prostatic tissue, including measures of 5-alpha-reductase isoenzymes and androgen receptors; (c) assessment of biological markers of genetic susceptibility, premalignant lesions (e.g., prostatic intraepithelial neoplasia), and later progressive stages of the carcinogenic process; (d) characterization of androgen receptor mutations and other molecular alterations at the gene and cellular levels; and (e) determination of risk associated with micronutrients and macronutrients (e.g., fatty acids) and interactions with hormones and hereditary factors. The objectives of this RFA were derived from the major recommendations of the workshop. Research Goals and Scope The purpose of this initiative is to stimulate innovative molecular epidemiologic research into the origins of prostate cancer, including the biological basis for the striking increase in prostate cancer incidence with age. Collaborations of several disciplines and research institutions are encouraged with utilization of shared laboratory and specimen resources whenever possible. Applications will be welcomed from investigators who are participating in ongoing collaborative organizations such as the George M. O'Brien Kidney and Urologic Research Centers, the Specialized Programs of Research Excellence in Prostate Cancer (SPORES), the NIEHS Environmental Health Sciences Centers and the General Clinical Research Centers (GCRCs). It is suggested that the collaborative organization be identified as the resource for conducting the proposed research, and a letter of agreement from the program director or principal investigator be included with the application. Proposals to expand an ongoing epidemiologic study by the addition of a laboratory component will be considered. Transitional molecular epidemiology studies characterizing and validating biomarkers while determining optimal biological specimens and the most suitable procedures for collection, processing, and storage are of particular interest. Selected measurements or biomarkers should be relevant to the processes of prostate carcinogenesis. Additionally, there is a need for demonstration of the utility of hormonal biomarkers with an evaluation of sensitivity, specificity, intra- and inter-individual variability. We strongly encourage investigations in understudied populations and in study populations of contrasting risk. Projects will be evaluated on the basis of their potential for enhancing understanding of prostate cancer etiology. The initiative invites a range of epidemiologic and interdisciplinary investigations of prostate cancer including, but not limited to: o Epidemiologic studies to: a. evaluate prostate cancer risk of lifestyle factors (e.g., smoking, alcohol intake), occupation (e.g., cadmium and zinc exposures, rubber industry, farming), exposure to radiation (e.g., ionizing, electromagnetic, and ultraviolet), environmental hazards (e.g., organochlorine compounds including DDT, PCBs, and dioxins or other pesticides), dietary intake (e.g., fatty acids, vitamins A, D, and E), and xenoestrogens utilizing available biomarkers and sources of specimens (e.g., prostate tissue, prostatic fluid, blood components) whenever possible; b. assess interactions of the above factors or their interrelationships with biochemical parameters (e.g., growth factors, prolactin, steroid receptors, androgen conjugates, 5-alpha-reductase isoenzymes); o Epidemiologic studies to identify risk factors (e.g., environmental, hormonal, viral exposure, sexually transmitted diseases, lifestyle, ethnicity) associated with benign prostatic hyperplasia or chronic prostatitis and to clarify their possible relationships to prostate cancer; o Population-based studies of the relationship between prostatic intraepithelial neoplasia, dysplasia, atypical hyperplasia, and invasive prostate cancer; o Analytic epidemiologic studies utilizing developed markers (e.g., biologic, biochemical, morphologic) to identify premalignant processes or risk factors (e.g., hormonal, environmental) that contribute to prostate carcinogenesis, including the transition from latent to invasive cancer; o Studies to further develop identified biomarkers (e.g., androgen receptor mutations, 5-alpha-reductase isoenzymes, epithelial cell receptors) for application in epidemiologic research by characterization and validation (in the laboratory and in humans) including consideration of biologic variables, e.g., age, genetic predisposition, ethnicity, nutritional status, hormonal profiles, preexisting disease and lifestyle; o Experimental laboratory or population-based studies to explore and elucidate the role of timing of environmental exposures during critical developmental and other time periods (e.g., fetal period, the window from birth to puberty, puberty, after castration or vasectomy) of the prostate gland relevant to future risk of carcinogenesis including, but not limited to: (a) cellular, genetic, and hormonal effects of environmental factors on normal and abnormal prostate growth and development, and (b) mechanism of how environmental exposures acting as initiating or promoting agents during time periods of interest affect the latency of prostate cancer; o Biochemical epidemiologic studies to: a. validate and compare prostate tissue levels of hormones (e.g., androgens, estrogens), their metabolites and receptors with other sources of specimens such as blood components and prostatic fluid; b. evaluate panels of circulating hormones (e.g., dihydrotestosterone [DHT] and its precursors, testosterone, DHEAS, DHEA, androstenedione and its metabolites such as DHT sulfate, DHT glucuronide, 3-alpha-diol glucuronide) in populations of varying risk, including men younger than 50 years old; o Molecular epidemiology studies to explore differences in genetic predisposition to prostate cancer due to variations in susceptibility genes, hormone metabolism, DNA repair activities, chromosome sensitivity to mutagens or other factors. SPECIAL REQUIREMENTS Awardees under this RFA are strongly encouraged to participate in two (2), one-day meetings to be held in Bethesda, Maryland, during the second and fifth years of the grant. Program directors from the NCI, NIDDK, and NIEHS will coordinate these meetings which will provide the opportunity for principal investigators to discuss their work in progress and to consider methodological and scientific issues. Applicants may request sufficient funds in the budget to accommodate expenses for one to two participants at each meeting. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH-supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research," which was reprinted in the Federal Register of March 28, 1994 (59 FR 14508-14513) to correct typesetting errors in the earlier publication, and reprinted in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23, Number 11. Investigators may obtain copies from these sources or from the program staff or contact person listed below. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are encouraged to submit, by October 17, 1994, a letter of intent that includes a descriptive title of the proposed research, the name and address of the principal investigator, the names of other key personnel, participating institutions, number and title of the RFA in response to which the application may be submitted, and estimated amount of direct costs if anticipated to exceed $500,000 for any year. Potential applicants for research of this magnitude are encouraged to contact the NCI prior to making detailed plans or submitting their application(s). Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications, including the avoidance of conflict of interest. The letter of intent is to be sent to: Dr. Kumiko Iwamoto National Cancer Institute Executive Plaza North, Suite 535 Bethesda, MD 20892 Telephone: (301) 496-9600 FAX: (301) 402-4279 APPLICATION PROCEDURES Applications are to be submitted on form PHS 398 (rev. 9/91), available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants (DRG), National Institutes of Health, Room 449, Westwood Building, Bethesda, MD 20892, telephone (301) 594-7248. The format and instructions applicable to research grant applications must be followed. The RFA label available in the application form PHS 398 (rev. 9/91) must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the number and title of the RFA must be typed on line 2a of the face page of the application and YES must be checked. Applications for the FIRST Award (R29) must include at least three sealed letters of reference attached to the face page of the original application. FIRST Award (R29) applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. Submit a signed, typewritten original of the application, including the Checklist, and three signed clear and single-sided photocopies in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, send two additional copies of the application to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute Executive Plaza North, Suite 636 Bethesda, MD 20892 Applications must be received by November 23, 1994. If an application is received after that date, it will be returned without review. The DRG will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application, and no application will be accepted that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by the DRG and for responsiveness by the NCI, NIDDK, and NIEHS. Incomplete applications will be returned to the applicant without further consideration. If the application is determined to be nonresponsive to the RFA, it will be returned without further consideration. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NCI, NIDDK, and NIEHS in accordance with the review criteria stated below. As part of the initial merit review, a process (triage) may be used by the initial review group in which applications will be determined to be competitive or non-competitive based on their scientific merit relative to other applications received in response to this RFA. Applications judged to be competitive will be discussed and assigned a priority score. Applications determined to be non-competitive will be withdrawn from further consideration and the principal investigator/program director and the official signing for the applicant organization will be promptly notified. The peer review will be followed by a second level of review by the National Cancer Advisory Board, the National Advisory Council for Diabetes and Digestive and Kidney Diseases, and the National Advisory Environmental Health Sciences Council to consider the special needs of each Institute. Review criteria for RFAs are generally the same as those for unsolicited research grant applications: o scientific, technical, or medical significance and originality of the proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the principal investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of resources necessary to perform the research. The review group will critically examine the submitted budget and will recommend an appropriate budget and period of support for each scored application. AWARD CRITERIA The earliest anticipated date of award is July 1, 1995. The following will be considered in making funding decisions: o quality of the proposed project as determined by peer review; o availability of funds; o balance among research activities relevant to selected areas of programmatic emphasis. INQUIRIES Written and telephone inquiries concerning this RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct inquiries regarding programmatic issues to: Dr. Kumiko Iwamoto Epidemiology and Biostatistics Program National Cancer Institute Executive Plaza North, Suite 535 Bethesda, MD 20892 Telephone: (301) 496-9600 FAX: (301) 402-4279 Dr. David G. Longfellow Chemical and Physical Carcinogenesis Branch National Cancer Institute Executive Plaza North, Suite 700 Bethesda, MD 20892 Telephone: (301) 496-5471 FAX: (301) 496-1040 Dr. Ralph L. Bain Urology Program National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 3A-05B Bethesda, MD 20892 Telephone: (301) 594-7556 FAX: (301) 594-7501 Dr. Gwen W. Collman Chemical Exposures and Molecular Biology Branch National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, NC 27709 Telephone: (919) 541-4980 FAX: (919) 541-2843 Direct inquiries regarding fiscal matters to: Ms. Theresa A. Mercogliano Grants Administration Branch National Cancer Institute Executive Plaza South, Suite 242 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 243 FAX: (301) 496-8601 Ms. Trude McCain Division of Extramural Affairs National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 649 Bethesda, MD 20892 Telephone: (301) 496-7467 FAX: (301) 594-7594 Mr. David L. Mineo Grants Management Branch National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, NC 27709 Telephone: (919) 541-7628 FAX: (919) 541-2860 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.393, 93.849, and 93.894. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under HHS policies and grant regulations. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service (PHS) strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. References 1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43:7-26. 2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118:793-803. 3. Nomura AMY, Kolonel LN. Prostate cancer: a current perspective. Epid Rev 1991; 13:200-227. 4. Ross RK, Bernstein L, Judd H. Serum testosterone levels in young black and white men. J Natl Cancer Inst 1976;76:45-48. 5. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17:337-347. 6. Muir C, Waterhouse J, Mack T, et al, eds. Cancer incidence in five continents. Vol 5. Lyon, France:International Agency for Research on Cancer, 1987. (IARC scientific publication no. 88). 7. Giovannuci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85:1571-1579. 8. Ross RK, Shimizu H, Paganini-Hill A, et al. Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst 1987; 78:869-74. 9. Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 1988; 127:999-1012. 10. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol, Biomarkers & Prev 1993; 2:467-472. 11. Chiarodo A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res 1991; 51:2498-2505. 12. Bova GS, Carter BS, Bussemakers MJG, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993; 53:3869-3873. 13. Carter BS, Ewing CM, Ward WS, et al. Allelic loss on chromosomes 10q and 16q in human prostate cancer. Proc Natl Acad Sci 1990; 87:8751-8755. From owner-sci-resources@net.bio.net Mon Aug 08 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 7 August 1994 Date: 8 Aug 1994 19:40:20 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 125 Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <326qak$j0f@net.bio.net> NNTP-Posting-Host: net.bio.net This message contains a summary of the documents added to the NSF STIS system in the previous week. Reference material concerning STIS follows the summary. ------------------------------------------------------------------------ ** NEW DOCUMENTS ON STIS ** Document Type: News Title: President Clinton Appoints Science and Technology Advisors File size (bytes): 20267 STIS Filename: whpr941 Title: White House Releases National Science Policy Report File size (bytes): 5060 STIS Filename: whpr942 Title: Science in the National Interest File size (bytes): 49157 STIS Filename: whrpt941 Document Type: Program Guideline Title: NSF 94-100 - University-Industry Cooperative Research Programs in the Mathematical Sciences File size (bytes): 38407 STIS Filename: nsf94100 Title: Faculty Early Career Development (CAREER) Program File size (bytes): 30982 STIS Filename: nsf94101 Title: NSF 94-104 - Postdoctoral Research Associates in Computational Science and Engineering and Associates in Experimental Science File size (bytes): 13645 STIS Filename: nsf94104 Title: NSF 94-106 - CISE Research Infrastructure Program File size (bytes): 35556 STIS Filename: nsf94106 Title: NSF 94-98 - SHEBA- Surface HEat Budget of the Arctic Ocean File size (bytes): 18600 STIS Filename: nsf9498 Document Type: Recruit Title: Secretary File size (bytes): 4988 STIS Filename: vgs94104 Title: Computer Specialist File size (bytes): 6726 STIS Filename: vgs94105 Title: Employee Relations Specialist File size (bytes): 6296 STIS Filename: vgs94106 Document Type: SRS Data Brief Title: DB 94-308 Federal Academic S&E Obligations Increased by 8 Percent in FY 1992 File size (bytes): 7279 STIS Filename: db94308 Also available: db94308.ps Title: DB 94-309 Federal Funding for R&D and for R&D Plant Expected to Decrease in FY 1994 File size (bytes): 6593 STIS Filename: db94309 Also available: db94309.ps Title: DB 94-310 Changes in the Immigration Law of 1990 Stimulate Major Increases in Immigrant Scientists & Engineers File size (bytes): 9414 STIS Filename: db94310 Also available: db94310.ps Title: DB 94-310 Changes in the Immigration Law of 1990 Stimulate Major Increases in Immigrant Scientists & Engineers File size (bytes): 9414 STIS Filename: db94310 Also available: db94310.ps ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserve@nsf.gov (Internet). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve db94310, the text of your message should be as follows: get db94310 Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve db94310, you would enter: ftp> get db94310 WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "pubs@nsf.gov" (Internet). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet). From owner-sci-resources@net.bio.net Wed Aug 10 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 23, no. 30, pt. 1of1, 12 August 1994 Date: 11 Aug 1994 13:06:10 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 873 Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <32e0bi$l5@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19940812 V23N30 P1O1 ************************************ X-comment: RFAs described: DK-94-023, AG-94-003 NIH GUIDE - Vol. 23, No. 30 - August 12, 1994 $$INDEX BEGIN ****